secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-207549
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q1 2026 revenue $1.0M, net loss $28.7M, cash funds into H2 2027
---------------------------------------------------------------------

- Revenue $1.0M vs $2.2M Q1 2025; net loss $28.7M vs $34.1M; R&D expenses $21.9M down from $29.8M.
- Cash and equivalents $128.1M plus $5M restricted cash, funding operations into second half of 2027.
- Phase 3 study of TSC-101 planned to start Q2 2026; early Cohort C data expected Q2 2026.
- Phase 1 trial of TSC-102-A01/A03 targeting CD45 to initiate in second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/0001193125-26-207549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526207549/tcrx-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-207549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer